KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) FCF Margin (2016 - 2025)

Ionis Pharmaceuticals has reported FCF Margin over the past 17 years, most recently at 53.13% for Q4 2025.

  • Quarterly results put FCF Margin at 53.13% for Q4 2025, up 938.0% from a year ago — trailing twelve months through Dec 2025 was 54.5% (up 2296.0% YoY), and the annual figure for FY2025 was 28.51%, up 4895.0%.
  • FCF Margin for Q4 2025 was 53.13% at Ionis Pharmaceuticals, up from 87.23% in the prior quarter.
  • Over the last five years, FCF Margin for IONS hit a ceiling of 6951.65% in Q2 2025 and a floor of 134.53% in Q4 2022.
  • Median FCF Margin over the past 5 years was 54.64% (2021), compared with a mean of 305.25%.
  • Biggest five-year swings in FCF Margin: tumbled -46984bps in 2022 and later surged 700764bps in 2025.
  • Ionis Pharmaceuticals' FCF Margin stood at 335.31% in 2021, then tumbled by -140bps to 134.53% in 2022, then surged by 108bps to 10.38% in 2023, then plummeted by -702bps to 62.51% in 2024, then increased by 15bps to 53.13% in 2025.
  • The last three reported values for FCF Margin were 53.13% (Q4 2025), 87.23% (Q3 2025), and 6951.65% (Q2 2025) per Business Quant data.